Acceder

Publicaciones - ONCOLOGÍA CLÍNICA Y TRASLACIONAL

Cargando...
Vergote I, Perez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martinez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Hogdall E, Farinas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. PubMed PMID: 37669480.
AÑO: 2023; IF: 42.1
37669480
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez Garcia J, Petru E, Kocian R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier E, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. PubMed PMID: 37643382; PubMed Central PMCID: PMC10602539.
AÑO: 2023; IF: 42.1
37643382
Sanchez Martinez DA, Salas-Lucia F, Jiang H, Ruiz-Carreno P, Alonso Romero JL. Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact. BMC Health Serv Res. 2022 Jul 26;22(1):948. doi: 10.1186/s12913-022-08222-9. PubMed PMID: 35883128; PubMed Central PMCID: PMC9316356.
AÑO: 2022; IF: 2.908
35883128
Escudero-Ortiz V, Dominguez-Lenero V, Catalan-Latorre A, Rebollo-Liceaga J, Sureda M. Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study. Pharmaceutics. 2022 Jun 8;14(6):1216. doi: 10.3390/pharmaceutics14061216. PubMed PMID: 35745789; PubMed Central PMCID: PMC9228468.
AÑO: 2022; IF: 6.525
35745789
Antonio CCP, Alida GG, Elena GG, Rocio GS, Jeronimo MG, Luis ARJ, Anibal ND, Francisco BV, Jesus GRA, Pablo RR, Jose GM. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. PubMed PMID: 34812982.
AÑO: 2022; IF: 3.7
34812982
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

ONCOLOGÍA CLÍNICA Y TRASLACIONAL